Collaborative Arrangements (Details 2) (GSK, USD $) In Millions, unless otherwise specified	3 Months Ended	9 Months Ended
Sep. 30, 2013	Sep. 30, 2013
GSK
Information related to collaborative arrangements
Reimbursement of certain research and development costs to the entity	$ 0.2	$ 0.5

Represents the amount of research reimbursement recognized under the collaborative arrangement by the entity as a result of reduction in research and development expense.

No definition available.

Name:	thrx_CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration